DAIC
JANUARY 8, 2025
a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases, hasannounced that the U.S. I look forward to conducting this innovative trial with Mineralys and our academic partners over the coming months.
Cardiometabolic Health Congress
JULY 25, 2024
This fall, we come together for the largest and most innovative cardiometabolic event in honor of the legacy of Dr. George L. Practical, Future-Focused Education Cardiorenal and metabolic diseases, fueled by poor lifestyle choices and health conditions, lead to type 2 diabetes, cardiovascular disease, and chronic kidney disease.
DAIC
JANUARY 18, 2024
The Summa Finesse Injectable has tremendous market potential and may become the standard of care when treating patients with chronic kidney disease, for whom contrast sparing is paramount.” The Summa Finesse Injectable is the first hybrid catheter launched in the planned line of interventional radiology devices from Summa.
Cardiometabolic Health Congress
OCTOBER 10, 2024
These innovative companies leverage AI to develop cutting-edge diagnostic tools, predictive analytics, and personalized medicine approaches. These companies are at the forefront of innovation, driving improvements in patient outcomes and reshaping the future of healthcare delivery.
Cardiometabolic Health Congress
AUGUST 14, 2024
This October, we gather for the largest and most innovative cardiometabolic event, honoring Dr. Bakris’ profound impact on our community. With his support, CMHC has championed a vision of a brighter future for clinicians, patients, and the entire healthcare sector.
GEMMS
MAY 22, 2024
In this article, we will explore the top 10 trends shaping the future of cardiovascular medicine, highlighting the innovative technologies and approaches that are revolutionizing the field. Genetic testing and DNA sequencing improve the accuracy of predicting heart disease risk.
Cardiometabolic Health Congress
OCTOBER 26, 2023
2023 conference, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) still list NASH and NAFLD as the official terms for conditions in which inflammation and fat cause damage to the liver. Nonalcoholic fatty liver disease (NAFLD) & NASH. As of the Oct. 78(1), pp. doi: 10.1097/hep.0000000000000412.
Expert insights. Personalized for you.
52 
Let's personalize your content